A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.

After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...

NXP800, a GCN2 kinase activator, has been on shaky ground since a data drop in November revealed a lack of efficacy. Seeking to improve outcomes, Nuvectis turned its attention to a new cohort of ...